Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Nasal vs Injected Naloxone
NCT02598856Phase 1Completed
- Sponsor
- Norwegian University of Science and Technology
- Start
- Mar 2016
- Primary completion
- Dec 2016
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of naloxone in opioid overdose, sponsored by Norwegian University of Science and Technology. Primary endpoint: Peak plasma concentration at 4 days. Started Mar 2016; status: completed.
02
Drugs
naloxone
03
Conditions
opioid overdose
Beyond the preview
Go deeper on NCT02598856.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02598856.